全球精神分裂症藥物市場規模調查，按治療類別、療法、分銷渠道和地區預測 2022-2028

精神分裂症是一種嚴重的精神疾病，會導致對現實的異常解釋。

精神分裂症會引起幻覺和妄想、思想和行動障礙、言語和行為障礙、思維障礙、缺乏動力等各種症狀，並干擾日常生活。精神分裂症患病率的上升、對心理健康的認識不斷提高以及大公司的戰略舉措是推動全球市場需求的因素。例如，根據世界衛生組織 (WHO) 的估計，截至 2022 年，全球約有 2400 萬人，即每 300 人中有 1 人 (0.32%) 將受到精神分裂症的影響。在成人中，這一比例為 222 分之 1（0.45%）。此外，市場見證了主要市場參與者的多項戰略舉措，包括最近的產品批准和合作夥伴關係，預計這些舉措將影響全球精神分裂症藥物市場的增長。例如，2021 年 9 月，強生公司獲得了美國食品和藥物管理局 (FDA) 對長效非典型抗精神病藥物 INVEGA HAFYERA（棕櫚酸帕利□酮 6 個月）的批准。這種新藥每年註射兩次，用於治療成人精神分裂症。此外，2021 年 11 月，位於英國倫敦的 Sosei Heptares 和位於加利福尼亞州聖地亞哥的 Neurocrine Biosciences 將合作開髮用於精神分裂症和其他神經精神疾病的新型毒蕈鹼受體激動劑。此外，預計人口老齡化的增加以及焦慮和抑鬱的增加也將成為推動預測期內市場需求的因素。然而，缺乏對精神分裂症的認識以及與精神分裂症藥物相關的成癮性上升等阻礙了 2022-2028 年預測期間的市場增長。

全球精神分裂症藥物市場研究考慮的重點地區是亞太地區、北美、歐洲、拉丁美洲和世界其他地區。由於精神障礙發病率的增加和大公司的存在，北美已成為全球市場份額的主要地區。另一方面，預計亞太地區將在 2022-2028 年的預測期內呈現顯著的增長率。醫療保健行業的強勁增長和老年人口不斷增加等因素將為亞太地區的全球精神分裂症治療市場創造良好的增長前景。

本報告中包括的主要市場進入者是：

• Pfizer Inc.
• AbbVie
• AstraZeneca
• Bristol Myers Squibb
• Eli Lilly
• GlaxoSmithKline
• Johnson & Johnson
• Merck KGAA
• Minerva Neurosciences
• Novartis AG

本研究的目的是確定近年來各個細分市場和國家/地區的市場規模，並預測未來八年的價值。本報告旨在捕捉所研究的每個地區和國家的行業的定性和定量方面。此外，它還提供了有關關鍵方面的詳細信息，例如定義市場未來增長的驅動因素和挑戰。此外，報告還應詳細分析主要參與者的競爭格局和產品供應，以及微觀市場中可供利益相關者投資的機會。市場的詳細細分和子細分如下所述。

按治療類別

第二代

第三代

按治療

口服藥物

注射

按銷售渠道

醫院藥房

零售藥店

網上藥店

按地區

北美

美國

加拿大

歐洲

英國

德國

法國

西班牙

意大利

其他歐洲

亞太地區

中國

印度

日本

澳大利亞

韓國

其他亞太地區

拉丁美洲

巴西

墨西哥

世界其他地方

此外，本研究考慮的年份是：

過去幾年 - 2018 年、2019 年、2020 年

2021 年基準年

預測期 - 2022-2028

本報告的目標受眾是全球精神分裂症藥物市場。

主要諮詢公司和顧問

大公司、中型公司、中小企業

風險投資

增值經銷商 (VAR)

第三方知識提供者

投資銀行家

投資者

內容

第 1 章執行摘要

• 市場快照
• 2020-2028 年全球市場和細分市場估計和預測
  • 2020-2028 年按地區分列的全球精神分裂症藥物市場
  • 全球精神分裂症藥物市場：按治療類別，2020-2028 年
  • 2020-2028 年按治療劃分的全球精神分裂症藥物市場
  • 2020-2028 年全球精神分裂症藥物市場：按分銷渠道
• 主要趨勢
• 調查方法
• 調查先決條件

第 2 章全球精神分裂症藥物市場的定義和範圍

• 調查目的
• 市場定義和範圍
  • 調查範圍
  • 工業發展
• 調查年份
• 貨幣兌換率

第3章全球精神分裂症藥物市場動態

• 精神分裂症藥物市場影響分析（2020-2028）
  • 市場驅動力
    • 精神分裂症患病率上升
    • 提高對心理健康的認識
    • 主要市場參與者的戰略舉措
  • 市場挑戰
    • 對精神分裂症的認識不足
    • 與精神分裂症藥物相關的成癮發生率增加
  • 市場機會
    • 老年人口增加
    • 焦慮和抑鬱增加

第四章全球精神分裂症藥物市場行業分析

• 波特的 5 力模型
  • 供應商的議價能力
  • 買家的議價能力
  • 新進入者的威脅
  • 替代品的威脅
  • 競爭公司之間的敵對關係
  • 波特 5 力模型的未來方法（2018-2028）
• PEST 分析
  • 政治
  • 經濟
  • 社交
  • 技術
• 招商引資模式
• 分析師的結論和建議
• 熱門投資機會
• 制勝法寶

第 5 章風險評估：COVID-19 的影響

• 評估 COVID-19 對行業的整體影響
• COVID-19 之前和 COVID-19 之後的市場情景

第 6 章全球精神分裂症藥物市場，按治療類別

• 市場快照
• 全球精神分裂症藥物市場：按治療類別，性能潛力分析
• 2018-2028 年全球精神分裂症藥物市場、估計和預測（按治療類別）
• 精神分裂症藥物市場，細分分析
  • 第二代
  • 第三代

第 7 章：全球精神分裂症藥物市場，按治療分類

• 市場快照
• 全球精神分裂症藥物市場，治療表現 - 潛力分析
• 2018-2028 年全球精神分裂症藥物市場、估計和預測（按治療）
• 精神分裂症藥物市場，細分分析
  • 口服劑
  • 注入

第 8 章全球精神分裂症藥物市場，按分銷渠道

• 市場快照
• 全球精神分裂症藥物市場：按分銷渠道進行的性能潛力分析
• 2018-2028 年全球精神分裂症藥物市場、分銷渠道估計和預測
• 精神分裂症藥物市場，細分分析
  • 醫院藥房
  • 零售藥房
  • 在線藥店

第 9 章。全球精神分裂症藥物市場：區域分析

• 精神分裂症藥物市場，按地區劃分的市場快照
• 北美
  • 美國
    • 治療等級估計和預測，2018-2028
    • 治療方法的估計和預測，2018-2028
    • 2018-2028 年分銷渠道估算與預測
  • 加拿大
• 歐洲精神分裂症藥物市場概況
  • 英國
  • 德國
  • 法國
  • 西班牙
  • 意大利
  • 其他歐洲地區
• 亞太地區精神分裂症藥物市場概況
  • 中國
  • 印度
  • 日本
  • 澳大利亞
  • 韓國
  • 其他亞太地區
• 拉丁美洲精神分裂症藥物市場概覽
  • 巴西
  • 墨西哥
• 世界其他地區

第 10 章衝突信息

• 頂級市場策略
• 公司簡介
  • 輝瑞公司
    • 主要信息
    • 概覽
    • 財務（如果有數據）
    • 產品概覽
    • 近期發展狀況
  • AbbVie
  • AstraZeneca
  • Bristol Myers Squibb
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck KGAA
  • Minerva Neurosciences
  • Novartis AG

第 11 章研究過程

• 研究過程
  • 數據挖掘
  • 分析
  • 市場估算
  • 驗證
  • 出版
• 調查屬性
• 調查先決條件

Global Schizophrenia Drugs Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028.

Schizophrenia is a serious mental disorder in which people interpret reality abnormally. Schizophrenia results in different conditions such as hallucinations, delusions, disordered thinking and behavior, disorganized speech, trouble with thinking and lack of motivation that impairs daily functioning. The rising in prevalence of Schizophrenia and increasing awareness towards mental health as well as Strategic initiatives from leading market players are factors that are accelerating the global market demand. For instance, according to World Health Organization (WHO) estimates - as of 2022, Schizophrenia affects around 24 million people or 1 in 300 people (0.32%) worldwide. Among adults this rate is 1 in 222 people (0.45%). Furthermore, the market witnessed several strategic initiatives from leading market players including recent product approvals, and partnerships would influence the growth of Global Schizophrenia Drugs market. For instance, in September 2021, Johnson & Johnson received the U.S. Food and Drug Administration (FDA) approval for its long-acting atypical antipsychotic INVEGA HAFYERA (6-month paliperidone palmitate) drug. This new drug is twice-yearly injectable and intended for the treatment of schizophrenia in adults. Moreover, in November 2021, London, UK based Sosei Heptares and San Diego, California, USA based Neurocrine Biosciences entered in a Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders. Also, growing number of geriatric individuals coupled with increasing incidences of anxiety and depression are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, a lack of awareness towards Schizophrenia and increasing incidences of addiction associated with Schizophrenia drugs impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Schizophrenia Drugs Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the growing incidences of mental disorders and presence of leading market players. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as the thriving growth of the healthcare industry and rising geriatric population, would create lucrative growth prospects for the global Schizophrenia Drugs Market across the Asia Pacific region.

Major market players included in this report are:

Pfizer Inc.

AbbVie

AstraZeneca

Bristol Myers Squibb

Eli Lilly

GlaxoSmithKline

Johnson & Johnson

Merck KGAA

Minerva Neurosciences

Novartis AG

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Therapeutic Class

Second Generation

Third Generation

By Treatment

Oral

Injectable

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019, 2020

Base year - 2021

Forecast period - 2022 to 2028

Target Audience of the Global Schizophrenia Drugs Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million)
  • 1.2.1. Global Schizophrenia Drugs Market, by Region, 2020-2028 (USD Million)
  • 1.2.2. Global Schizophrenia Drugs Market, by Therapeutic Class, 2020-2028 (USD Million)
  • 1.2.3. Global Schizophrenia Drugs Market, by Treatment, 2020-2028 (USD Million)
  • 1.2.4. Global Schizophrenia Drugs Market, by Distribution Channel, 2020-2028 (USD Million)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Schizophrenia Drugs Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Scope of the Study
  • 2.2.2. Industry Evolution
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Schizophrenia Drugs Market Dynamics

• 3.1. Schizophrenia Drugs Market Impact Analysis (2020-2028)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Rise in prevalence of Schizophrenia
    • 3.1.1.2. Increasing awareness towards mental health.
    • 3.1.1.3. Strategic initiatives from leading market players.
  • 3.1.2. Market Challenges
    • 3.1.2.1. Lack of awareness towards Schizophrenia.
    • 3.1.2.2. Increasing incidences of addiction associated with Schizophrenia drugs
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Growing number of geriatric individuals.
    • 3.1.3.2. Increasing incidences of anxiety and depression.

Chapter 4. Global Schizophrenia Drugs Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2028)
• 4.2. PEST Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
• 4.3. Investment Adoption Model
• 4.4. Analyst Recommendation & Conclusion
• 4.5. Top investment opportunity
• 4.6. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

• 5.1.1. Assessment of the overall impact of COVID-19 on the industry
• 5.1.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Schizophrenia Drugs Market, by Therapeutic Class

• 6.1. Market Snapshot
• 6.2. Global Schizophrenia Drugs Market by Therapeutic Class, Performance - Potential Analysis
• 6.3. Global Schizophrenia Drugs Market Estimates & Forecasts by Therapeutic Class 2018-2028 (USD Million)
• 6.4. Schizophrenia Drugs Market, Sub Segment Analysis
  • 6.4.1. Second Generation
  • 6.4.2. Third Generation

Chapter 7. Global Schizophrenia Drugs Market, by Treatment

• 7.1. Market Snapshot
• 7.2. Global Schizophrenia Drugs Market by Treatment, Performance - Potential Analysis
• 7.3. Global Schizophrenia Drugs Market Estimates & Forecasts by Treatment 2018-2028 (USD Million)
• 7.4. Schizophrenia Drugs Market, Sub Segment Analysis
  • 7.4.1. Oral
  • 7.4.2. Injectable

Chapter 8. Global Schizophrenia Drugs Market, by Distribution Channel

• 8.1. Market Snapshot
• 8.2. Global Schizophrenia Drugs Market by Distribution Channel, Performance - Potential Analysis
• 8.3. Global Schizophrenia Drugs Market Estimates & Forecasts by Distribution Channel 2018-2028 (USD Million)
• 8.4. Schizophrenia Drugs Market, Sub Segment Analysis
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Retail Pharmacies
  • 8.4.3. Online Pharmacies

Chapter 9. Global Schizophrenia Drugs Market, Regional Analysis

• 9.1. Schizophrenia Drugs Market, Regional Market Snapshot
• 9.2. North America Schizophrenia Drugs Market
  • 9.2.1. U.S. Schizophrenia Drugs Market
    • 9.2.1.1. Therapeutic Class estimates & forecasts, 2018-2028
    • 9.2.1.2. Treatment estimates & forecasts, 2018-2028
    • 9.2.1.3. Distribution Channel estimates & forecasts, 2018-2028
  • 9.2.2. Canada Schizophrenia Drugs Market
• 9.3. Europe Schizophrenia Drugs Market Snapshot
  • 9.3.1. U.K. Schizophrenia Drugs Market
  • 9.3.2. Germany Schizophrenia Drugs Market
  • 9.3.3. France Schizophrenia Drugs Market
  • 9.3.4. Spain Schizophrenia Drugs Market
  • 9.3.5. Italy Schizophrenia Drugs Market
  • 9.3.6. Rest of Europe Schizophrenia Drugs Market
• 9.4. Asia-Pacific Schizophrenia Drugs Market Snapshot
  • 9.4.1. China Schizophrenia Drugs Market
  • 9.4.2. India Schizophrenia Drugs Market
  • 9.4.3. Japan Schizophrenia Drugs Market
  • 9.4.4. Australia Schizophrenia Drugs Market
  • 9.4.5. South Korea Schizophrenia Drugs Market
  • 9.4.6. Rest of Asia Pacific Schizophrenia Drugs Market
• 9.5. Latin America Schizophrenia Drugs Market Snapshot
  • 9.5.1. Brazil Schizophrenia Drugs Market
  • 9.5.2. Mexico Schizophrenia Drugs Market
• 9.6. Rest of The World Schizophrenia Drugs Market

Chapter 10. Competitive Intelligence

• 10.1. Top Market Strategies
• 10.2. Company Profiles
  • 10.2.1. Pfizer Inc.
    • 10.2.1.1. Key Information
    • 10.2.1.2. Overview
    • 10.2.1.3. Financial (Subject to Data Availability)
    • 10.2.1.4. Product Summary
    • 10.2.1.5. Recent Developments
  • 10.2.2. AbbVie
  • 10.2.3. AstraZeneca
  • 10.2.4. Bristol Myers Squibb
  • 10.2.5. Eli Lilly
  • 10.2.6. GlaxoSmithKline
  • 10.2.7. Johnson & Johnson
  • 10.2.8. Merck KGAA
  • 10.2.9. Minerva Neurosciences
  • 10.2.10. Novartis AG

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes
• 11.3. Research Assumption

LIST OF TABLES

• TABLE 1. Global Schizophrenia Drugs Market, report scope
• TABLE 2. Global Schizophrenia Drugs Market estimates & forecasts by Region 2018-2028 (USD Million)
• TABLE 3. Global Schizophrenia Drugs Market estimates & forecasts by Therapeutic Class 2018-2028 (USD Million)
• TABLE 4. Global Schizophrenia Drugs Market estimates & forecasts by Treatment 2018-2028 (USD Million)
• TABLE 5. Global Schizophrenia Drugs Market estimates & forecasts by Distribution Channel 2018-2028 (USD Million)
• TABLE 6. Global Schizophrenia Drugs Market by segment, estimates & forecasts, 2018-2028 (USD Million)
• TABLE 7. Global Schizophrenia Drugs Market by region, estimates & forecasts, 2018-2028 (USD Million)
• TABLE 8. Global Schizophrenia Drugs Market by segment, estimates & forecasts, 2018-2028 (USD Million)
• TABLE 9. Global Schizophrenia Drugs Market by region, estimates & forecasts, 2018-2028 (USD Million)
• TABLE 10. Global Schizophrenia Drugs Market by segment, estimates & forecasts, 2018-2028 (USD Million)
• TABLE 11. Global Schizophrenia Drugs Market by region, estimates & forecasts, 2018-2028 (USD Million)
• TABLE 12. Global Schizophrenia Drugs Market by segment, estimates & forecasts, 2018-2028 (USD Million)
• TABLE 13. Global Schizophrenia Drugs Market by region, estimates & forecasts, 2018-2028 (USD Million)
• TABLE 14. Global Schizophrenia Drugs Market by segment, estimates & forecasts, 2018-2028 (USD Million)
• TABLE 15. Global Schizophrenia Drugs Market by region, estimates & forecasts, 2018-2028 (USD Million)
• TABLE 16. U.S. Schizophrenia Drugs Market estimates & forecasts, 2018-2028 (USD Million)
• TABLE 17. U.S. Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 18. U.S. Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 19. Canada Schizophrenia Drugs Market estimates & forecasts, 2018-2028 (USD Million)
• TABLE 20. Canada Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 21. Canada Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 22. UK Schizophrenia Drugs Market estimates & forecasts, 2018-2028 (USD Million)
• TABLE 23. UK Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 24. UK Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 25. Germany Schizophrenia Drugs Market estimates & forecasts, 2018-2028 (USD Million)
• TABLE 26. Germany Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 27. Germany Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 28. RoE Schizophrenia Drugs Market estimates & forecasts, 2018-2028 (USD Million)
• TABLE 29. RoE Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 30. RoE Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 31. China Schizophrenia Drugs Market estimates & forecasts, 2018-2028 (USD Million)
• TABLE 32. China Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 33. China Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 34. India Schizophrenia Drugs Market estimates & forecasts, 2018-2028 (USD Million)
• TABLE 35. India Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 36. India Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 37. Japan Schizophrenia Drugs Market estimates & forecasts, 2018-2028 (USD Million)
• TABLE 38. Japan Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 39. Japan Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 40. RoAPAC Schizophrenia Drugs Market estimates & forecasts, 2018-2028 (USD Million)
• TABLE 41. RoAPAC Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 42. RoAPAC Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 43. Brazil Schizophrenia Drugs Market estimates & forecasts, 2018-2028 (USD Million)
• TABLE 44. Brazil Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 45. Brazil Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 46. Mexico Schizophrenia Drugs Market estimates & forecasts, 2018-2028 (USD Million)
• TABLE 47. Mexico Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 48. Mexico Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 49. RoLA Schizophrenia Drugs Market estimates & forecasts, 2018-2028 (USD Million)
• TABLE 50. RoLA Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 51. RoLA Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 52. Row Schizophrenia Drugs Market estimates & forecasts, 2018-2028 (USD Million)
• TABLE 53. Row Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 54. Row Schizophrenia Drugs Market estimates & forecasts by segment 2018-2028 (USD Million)
• TABLE 55. List of secondary sources, used in the study of global Schizophrenia Drugs Market
• TABLE 56. List of primary sources, used in the study of global Schizophrenia Drugs Market
• TABLE 57. Years considered for the study
• TABLE 58. Exchange rates considered

LIST OF FIGURES

List of figures

• FIG 1. Global Schizophrenia Drugs Market, research methodology
• FIG 2. Global Schizophrenia Drugs Market, Market estimation techniques
• FIG 3. Global Market size estimates & forecast methods
• FIG 4. Global Schizophrenia Drugs Market, key trends 2021
• FIG 5. Global Schizophrenia Drugs Market, growth prospects 2022-2028
• FIG 6. Global Schizophrenia Drugs Market, porters 5 force model
• FIG 7. Global Schizophrenia Drugs Market, pest analysis
• FIG 8. Global Schizophrenia Drugs Market, value chain analysis
• FIG 9. Global Schizophrenia Drugs Market by segment, 2018 & 2028 (USD Million)
• FIG 10. Global Schizophrenia Drugs Market by segment, 2018 & 2028 (USD Million)
• FIG 11. Global Schizophrenia Drugs Market by segment, 2018 & 2028 (USD Million)
• FIG 12. Global Schizophrenia Drugs Market by segment, 2018 & 2028 (USD Million)
• FIG 13. Global Schizophrenia Drugs Market by segment, 2018 & 2028 (USD Million)
• FIG 14. Global Schizophrenia Drugs Market, regional snapshot 2018 & 2028
• FIG 15. North America Schizophrenia Drugs Market 2018 & 2028 (USD Million)
• FIG 16. Europe Schizophrenia Drugs Market 2018 & 2028 (USD Million)
• FIG 17. Asia pacific Market 2018 & 2028 (USD Million)
• FIG 18. Latin America Schizophrenia Drugs Market 2018 & 2028 (USD Million)
• FIG 19. Global Schizophrenia Drugs Market, company Market share analysis (2021)